An important paper describing genetic factors involved in blood pressure and heart disease was published this week. 29 loci were identified - 16 of these novel. This is impressive, but not so surprising as both diastolic and systolic blood pressure are complex, heritable traits. Many, many factors are at play here. In fact, the authors describe a risk score based on genotypes at 29 genome-wide significant variants, which was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function.
Some time ago, I wrote about the genome of the SHR (spontaneous hypertensive rat). This rat and the FHH strain are models for hypertension. The genome of the SHR strain showed that 788 genes contained variants with respect to the reference rat genome. Whether any or all of those variants function in producing the hypertension phenotype is not clear, but reasoning went that these variants would be a logical place from which to build list of candidate genes.
Well, I thought it would be a fun and quick exercise to see how many of these 29 loci detected by genome-wide associations in nearly 70,000 individuals of European ancestry (with validation of top signals in up to 133,000 additional individuals of European descent) compare to those genes that possess genetic variants in either the FHH or SHR rat strains. This may give insight into the applicability of sequencing the genomes of specific model organism strains and into how many or how often genes are identified by both GWAS and whole-genome sequencing. To do this, I used the Rat Genome Browser hosted by the Medical College of Wisconsin.
Of the 29 human loci, 23 map in the rat genome within a QTL for blood pressure. This looks good, but consider that there are numerous blood pressure (BP) QTL mapped throughout the rat genome. In fact, the rat Adm gene maps within 27 different BP QTL and three other gene regions, Furin - Fes, Plekha7 and Mov10, map within more than 20 different BP QTL. Some of these QTL are large, spanning many genes, which means that fine-mapping is needed - such as a GWAS - to identify more precisely candidate loci.
Only 18 of the human BP genes identified in the paper contain SNPs in either the FHH or SHR strains. Often, the variants are shared in both strains. Both synonymous and nonsynonymous SNPs were noted, but synonymous far outnumbered those variants that altered the underlying amino acid sequence. No SNPs in gene control regions were noted, which may indeed be the case or a limitation of the data sources used here.
The human genes whose rat versions contain SNPs in the hypertensive-susceptible strains are:
SLC39A8
ATP2B1
GNAS - EDN3
MTHFR - NPPB
FGF5
CYP1A1 - ULK3
FURIN - FES
FLJ32810 - TMEM133
NPR3 - C5orf23
EBF1
PLCE1
BAT2-BAT5
ZNF652
TBX5 - TBX3
JAG1
GUCY1A3 - GUCY1B3
MECOM
ULK4
SNPs altering gene expression still need to be added to this analysis. Nonetheless, the numbers and types of genes that share genetic variation in hypertensive mammals (human, rat) is revealing. It is likely that the 788 identified genes with variation in the SHR rat are not all important for hypertension, but that strain does carry variants in 17 of these new BP genes. Or is that just 17?
Showing posts with label synonymous SNP. Show all posts
Showing posts with label synonymous SNP. Show all posts
Tuesday, September 13, 2011
Wednesday, February 2, 2011
Synonymous SNPs are not so synonymous
Early this week, an excellent paper by Brest, Darfeuille-Michaud, Hofman, et al. in Nature Genetics provides a prime example of going beyond genome-wide association studies (GWAS) to dissect the functional consequences of a genetic variant associated with disease risk. In so doing, the authors provide another case of synonynous SNPs not being so synonymous.
Here are what I find to be the key points of the research presented in this report:
1. The exonic SNP c.313C>T (rs10065172) is in perfect linkage disequilibrium (r2=1.0) with a deletion polymorphism of 20 kbp mapping upstream of the IRGM gene. This deletion has been strongly associated with Crohn's disease in several European populations or those with European ancestry. What is important here is a SNP can act as a tag or proxy for the deletion.
2. The c.313C>T variant alters codon 105 of the IRGM protein from CTG>TTG. Both codons call for leucine upon translation and so this SNP is classified as synonymous. The authors speculate that there could be allele-specific consequences to protein expression. Based on two other reports from other groups, the authors decided to investigate whether allele-specific interactions between the IRGM transcript and a microRNA could be at play here. They observed a predicted binding between microRNA-196 (or miR-196, both miR-196A encoded by A1 and A2 genes and by miR-196B) that was affected by the variation at SNP c.313C>T. Importantly, they show that not only is the miR-196-IRGM interaction real but that expression of miR-196 is elevated in inflammatory epithelia from Crohn's sufferers. These results underscore the point that synonymous SNPs are not so synonymous. The different alleles can exhibit different functions that have health consequences.
3. From GWAS to function. Although this paper does not report original results from GWAS, it builds on those results in an important way. There are four key papers reporting GWAS results for IRGM and Crohn's disease. These papers are by Parkes et al (2007), the Wellcome Trust Case Control Consortium (2007), Barrett et al (2008) and Franke et al (2010). So, in just over three years from the initial discovery of association of this once rather unremarkable gene (only 5 papers were published on IRGM prior to the initial GWAS report of 2007, most reporting a role in autophagy), we now have a much deeper understanding how a synonymous variant leads to the disease condition.
This is very nice work indeed and can be held up as an example of the success of GWAS in laying a foundation for getting at the mechanism of a disease.
Here are what I find to be the key points of the research presented in this report:
1. The exonic SNP c.313C>T (rs10065172) is in perfect linkage disequilibrium (r2=1.0) with a deletion polymorphism of 20 kbp mapping upstream of the IRGM gene. This deletion has been strongly associated with Crohn's disease in several European populations or those with European ancestry. What is important here is a SNP can act as a tag or proxy for the deletion.
2. The c.313C>T variant alters codon 105 of the IRGM protein from CTG>TTG. Both codons call for leucine upon translation and so this SNP is classified as synonymous. The authors speculate that there could be allele-specific consequences to protein expression. Based on two other reports from other groups, the authors decided to investigate whether allele-specific interactions between the IRGM transcript and a microRNA could be at play here. They observed a predicted binding between microRNA-196 (or miR-196, both miR-196A encoded by A1 and A2 genes and by miR-196B) that was affected by the variation at SNP c.313C>T. Importantly, they show that not only is the miR-196-IRGM interaction real but that expression of miR-196 is elevated in inflammatory epithelia from Crohn's sufferers. These results underscore the point that synonymous SNPs are not so synonymous. The different alleles can exhibit different functions that have health consequences.
3. From GWAS to function. Although this paper does not report original results from GWAS, it builds on those results in an important way. There are four key papers reporting GWAS results for IRGM and Crohn's disease. These papers are by Parkes et al (2007), the Wellcome Trust Case Control Consortium (2007), Barrett et al (2008) and Franke et al (2010). So, in just over three years from the initial discovery of association of this once rather unremarkable gene (only 5 papers were published on IRGM prior to the initial GWAS report of 2007, most reporting a role in autophagy), we now have a much deeper understanding how a synonymous variant leads to the disease condition.
This is very nice work indeed and can be held up as an example of the success of GWAS in laying a foundation for getting at the mechanism of a disease.
Subscribe to:
Posts (Atom)